Has tucatinib/tucatinib been officially approved in China?

Tucatinib is a small molecule tyrosine kinase inhibitor targeting the HER2 receptor. It is widely used to treat HER2-positive metastatic breast cancer, especially in patients with brain metastases. It shows good therapeutic prospects. Although this drug has been approved for marketing in many countries and regions including the United States, the European Union, and Canada, and has been included in the standard treatment option for HER2-positive breast cancer, so far, tucatinib has not yet received official marketing approval from the National Medical Products Administration (NMPA) in mainland China. This means that patients within mainland China are not yet able to obtain prescription treatment for this drug through conventional channels.

However, this does not mean that tucatinib lacks attention in China. In recent years, as China's review and approval of innovative anti-tumor drugs has accelerated, the local clinical research and registration process of this drug has also gradually advanced. Tertiary hospitals in many places in China have participated in international multi-center clinical studies, providing important data support for the registration of tucatinib in China. At the same time, Hong Kong, China, has taken the lead in approving the marketing of tucatinib, which not only brings more hope to Chinese patients to obtain the drug, but is also regarded as an important indicator of its future approval in the mainland. Some mainland patients can obtain drugs through cross-border drug purchase, overseas medical treatment or informal channels through third-party platforms. However, this process requires weighing many factors such as the source of the drug, drug safety and legality.

The key reason why tucatinib has attracted so much attention lies in its unique value in the treatment ofHER2-positive breast cancer, especially cases of brain metastasis. Traditional HER2-targeted therapies have certain limitations in penetrating the blood-brain barrier. Tucatinib, with its molecular structure, has stronger distribution ability in the central nervous system, providing a new hope for patients with brain metastases.

Reference materials:https://www.tukysa.com/